Berry Genomics

Company Overview

Berry Genomics is focused on developing new DNA sequencing technologies for clinical genetic testing and providing next-generation sequencing technology service for all scientific researchers in life science, disease research and other biological and medical fields. Berry Genomics, a pioneer in clinical genomics and life science in China, was established in May 2010. Berry Genomics is committed to the study, creation, and distribution of genetic diagnostic technology for medical use. The organisation wants to help with precise disease diagnosis throughout the entire human life cycle and to enhance health. Berry Genomics, a business with significant R&D capabilities, developed the first NGS-based genetic test, NIPT, in China in 2010. From conception to adulthood, the business currently offers NGS-based tests for a variety of genetic illnesses and malignancies. In the international clinical investigation of early clinical detection of liver cancer, Berry Genomics is at the forefront. Third-generation sequencing technology is now being investigated in both clinical settings and academic research. Around 1500 people work for Berry Genomics, which develops products and offers services to more than 4000 businesses and institutions both domestically and internationally, including hospitals, research institutions, universities, and enterprises.

Financial Highlights (FY 2023)

Company's Business Segments

• Reagent Sales : DNA extraction reagents, DNA purification reagents, Library preparation reagents, and Sequencing reagents
• Medical Testing Service : Clinical report including the test results and Clinical diagnosis
• Basic Scientific Research Service : Genomic research, Multi-sample pan-genome research, Genome haplotype typing, PacBio and Revio sequencing platforms, T2T (Telomere-to-Telomere) genome solution, Quadratinized T2T solutions, Three generations of low-depth human resequencing products, Three generations of methylation products, Three generations of microbial products